EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access

23 May 2017

The European Semester Country Specific Recommendations show that healthcare systems […]

Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe

9 May 2017

The new report on The Impact of Biosimilar Competition in […]

Industry Welcomes the 3^rd European Commission Workshop on Biosimilar Medicines

5 May 2017

The European pharmaceutical industry welcomes the 3rd workshop on access […]

Over 100 Participants Explore Opportunities to Ensure Universal Access to Health

27 April 2017

Over 100 participants explored different ways and opportunities to ensure […]

Biosimilars at work: Access. Experience. Science.

1 April 2017

Biosimilar medicines are a part of today’s therapeutic armamentarium – […]

Biosimilar Medicines: a Game Changer for Oncology Care

23 March 2017

With 10 years of positive experience with biosimilar medicines, medical […]

Access to Medicines at Sustainable Price: Pharma Industry and Governments Transforming Challenges into Opportunities

23 March 2017

Stimulating Investment in European Generic, Biosimilar and Value Added Medicines through a Transparent Legal Environment

22 March 2017

Key authorities, eminent lawyers and industry leaders discussed today in […]

Biosimilar interchangeability: Do you know your switching from your substitution?

21 March 2017

US FDA interchangeability guidance adds another level of confusion over […]

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

14 March 2017

On 9th March, IFPMA launched jointly with EFPIA and EBE […]